Eli Lilly are two of the largest players in the market for weight loss medication in the US, where Zepbound and Wegovy respectively compete for patients' favor. (Archive photo). Photo: Reuters/Reuters
Novo sues competitor for misleading marketing
Novo Nordisk has filed a lawsuit against Eli Lilly, claiming the company misled patients in US marketing for its weight-loss drugs Zepbound and Mounjaro.
According to Novo, Eli Lilly used outdated studies comparing the maximum allowed dose of Zepbound to lower doses of Novo’s Wegovy, failing...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?